Dossier assessment
Blinatumomab (B-ALL, refractory or relapsed, children and adolescents >= 1 month) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Blinatumomab (B-ALL, refractory or relapsed, children and adolescents >= 1 month) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Blinatumomab (B-ALL, refractory or relapsed, children and adolescents >= 1 month) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Paediatric patients aged 1 month or older with Philadelphia chromosome-negative CD19+ B-cell precursor acute lymphoblastic leukaemia which is refractory or in relapse after receiving at least 2 prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation
Added benefit not proven
Project details
- Project no.
- A26-58
- Commission
- Commission awarded on 29.05.2026 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A26-58
Connected Projects
-
Dossier assessment
Blinatumomab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V
Status: Commission completed
-
Dossier assessment
Blinatumomab (acute lymphoblastic leukaemia)- Assessment according to §35a (para. 1., sentence 10) Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Blinatumomab (ALL, paediatric patients) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Blinatumomab (ALL, MRD-positive patients) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Blinatumomab (acute lymphoblastic leukaemia, Ph-, CD19+, children aged 1 to 18 years) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Blinatumomab (acute lymphoblastic leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Blinatumomab (refractory ALL, children < 1 year) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Blinatumomab (first relapsed ALL, children < 1 year) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Blinatumomab (B-ALL, relapsed or refractory) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Blinatumomab (B-ALL, newly diagnosed, consolidation therapy) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Blinatumomab (B-ALL, high-risk first relapsed, children and adolescents >= 1 month) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Blinatumomab (B-ALL, 1st and 2nd complete remission) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed